These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7226501)

  • 1. Interference of levodopa and its metabolites with colorimetry of uric acid.
    Bierer DW; Quebbemann AJ
    Clin Chem; 1981 May; 27(5):756-8. PubMed ID: 7226501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
    Dethy S; Laute MA; Van Blercom N; Damhaut P; Goldman S; Hildebrand J
    Clin Chem; 1997 May; 43(5):740-4. PubMed ID: 9166225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
    Dutton J; Copeland LG; Playfer JR; Roberts NB
    Clin Chem; 1993 Apr; 39(4):629-34. PubMed ID: 8472357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
    Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y
    Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
    Serra PA; Esposito G; Enrico P; Mura MA; Migheli R; Delogu MR; Miele M; Desole MS; Grella G; Miele E
    Br J Pharmacol; 2000 Jun; 130(4):937-45. PubMed ID: 10864903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
    Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E
    Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of L-dopa on renal handling of uric acid.
    Bierer DW; Quebbemann AJ
    J Pharmacol Exp Ther; 1982 Oct; 223(1):55-9. PubMed ID: 7120128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
    Vieru E; Köksal A; Mutluay B; Dirican AC; Altunkaynak Y; Baybas S
    Neurol Sci; 2016 May; 37(5):743-7. PubMed ID: 26753800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure, aging, and renal synthesis of dopamine.
    Ferreira A; Bettencourt P; Pestana M; Correia F; Serrão P; Martins L; Cerqueira-Gomes M; Soares-Da-Silva P
    Am J Kidney Dis; 2001 Sep; 38(3):502-9. PubMed ID: 11532681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
    Rose S; Jenner P; Marsden CD
    J Pharm Pharmacol; 1991 May; 43(5):325-30. PubMed ID: 1680174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
    Betto P; Ricciarello G; Giambenedetti M; Lucarelli C; Ruggeri S; Stocchi F
    J Chromatogr; 1988 Dec; 459():341-9. PubMed ID: 3243910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
    Algeri S; Ruggieri S; Miranda F; Casacchia M; Morselli PL; Agnoli A
    Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease.
    Wenning GK; O'Connell MT; Patsalos PN; Quinn NP
    Mov Disord; 1995 Sep; 10(5):664-7. PubMed ID: 8552121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
    Pinheiro-Carrera M; Tomaz C; Huston JP; Dai H; Carey RJ
    Life Sci; 1994; 55(13):991-7. PubMed ID: 8084215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.